Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Other Accumulated Expenses (2019 - 2025)

Allogene Therapeutics' Other Accumulated Expenses history spans 4 years, with the latest figure at $1.8 million for Q4 2023.

  • For Q4 2023, Other Accumulated Expenses changed N/A year-over-year to $1.8 million; the TTM value through Dec 2023 reached $1.8 million, changed N/A, while the annual FY2023 figure was $1.8 million, N/A changed from the prior year.
  • Other Accumulated Expenses for Q4 2023 was $1.8 million at Allogene Therapeutics, up from $1.7 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $4.8 million in Q4 2020 and bottomed at $1.4 million in Q1 2019.
  • The 4-year median for Other Accumulated Expenses is $2.0 million (2019), against an average of $2.5 million.
  • The largest annual shift saw Other Accumulated Expenses soared 58.75% in 2020 before it crashed 63.58% in 2021.
  • A 4-year view of Other Accumulated Expenses shows it stood at $3.0 million in 2019, then skyrocketed by 58.75% to $4.8 million in 2020, then plummeted by 63.58% to $1.7 million in 2021, then increased by 3.67% to $1.8 million in 2023.
  • Per Business Quant, the three most recent readings for ALLO's Other Accumulated Expenses are $1.8 million (Q4 2023), $1.7 million (Q4 2021), and $4.8 million (Q4 2020).